Latest Breaking News On - Rob iannone - Page 1 : comparemela.com

Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024

/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings,.

ASCO: Jazz shares 'unprecedented' biliary tract cancer data

As zanidatamab awaits an FDA decision, Jazz is sharing long-term phase 2 data in advanced biliary tract cancer for the HER2-targeted bispecific antibody.

FDA Grants Priority Review for Zanidatamab to Treat HER2-Positive Metastatic Biliary Tract Cancer

FDA Grants Priority Review to Zanidatamab for HER2+ Metastatic Biliary Tract Cancer

Zanidatamab has received priority review from the FDA for the treatment of patients with HER2-positive metastatic biliary tract cancer.

Zanidatamab Gets Priority Review for HER2-Amplified Biliary Tract Cancer

Zanidatamab is a HER2-targeted bispecific antibody that can simultaneously bind 2 non-overlapping epitopes of the HER2 receptor.